Literature DB >> 15272921

The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.

Ki Won Oh1, Eun Jung Rhee, Won Young Lee, San Woo Kim, Eun Sook Oh, Ki Hyun Baek, Moo Il Kang, Moon Gi Choi, Hyung Joon Yoo, Sung Woo Park.   

Abstract

OBJECTIVE: Osteoprotegerin (OPG) is a recently identified cytokine that acts as a decoy receptor for the RANK ligand. Moreover, OPG has been shown to be an important inhibitor of osteoclastogenesis in animal models. However, the relationship between circulating OPG levels and female bone status in human populations is unclear. In this study we undertook to investigate the relationship between circulating OPG levels and bone mineral metabolism in healthy women. PATIENTS AND MEASUREMENTS: Our subjects were 287 women aged 37-73 years (mean age 51.5 years). The serum concentrations of OPG were determined by enzyme-linked immunosorbent assay (ELISA). The biochemical markers of bone turnover and FSH were measured using standard methods. Bone mineral densities at the lumbar spine and femoral neck were measured by dual-energy X-ray absorptiometry.
RESULTS: Postmenopausal women had a significantly higher mean value of serum OPG than premenopausal women (1358.5 +/- 32.5 pg/ml vs. 1228.8 +/- 33.3 pg/ml, P < 0.01). Serum OPG levels were positively correlated with age (r = 0.169, P < 0.01), as were urine deoxypyridinoline levels (r = 0.133, P < 0.05) and serum FSH levels (r = 0.187, P < 0.01) in a bivariate correlation analyses. In a multiple regression analysis, only urine calcium excretion was identified as a significant predictor for serum OPG levels.
CONCLUSIONS: Circulating OPG levels were found to be associated with urine calcium excretion and menopause in healthy women. Our observations suggest that circulating OPG levels reflect an antiresorptive activity in bone, and they are related to endogenous oestrogen levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272921     DOI: 10.1111/j.1365-2265.2004.02090.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

Review 2.  Inflammatory bowel diseases as secondary causes of osteoporosis.

Authors:  Charles N Bernstein
Journal:  Curr Osteoporos Rep       Date:  2006-09       Impact factor: 5.096

3.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

4.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

5.  The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.

Authors:  Anna Stern; Gail A Laughlin; Jaclyn Bergstrom; Elizabeth Barrett-Connor
Journal:  Eur J Endocrinol       Date:  2007-05       Impact factor: 6.664

6.  Insulin resistance and bone strength: findings from the study of midlife in the United States.

Authors:  Preethi Srikanthan; Carolyn J Crandall; Dana Miller-Martinez; Teresa E Seeman; Gail A Greendale; Neil Binkley; Arun S Karlamangla
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

7.  OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

Authors:  Andrea Z LaCroix; Rebecca D Jackson; Aaron Aragaki; Charles Kooperberg; Jane A Cauley; Zhao Chen; Meryl S Leboff; David Duggan; Jean Wactawski-Wende
Journal:  Bone       Date:  2013-06-02       Impact factor: 4.398

8.  Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip.

Authors:  Elizabeth J Samelson; Kerry E Broe; Serkalem Demissie; Thomas J Beck; David Karasik; Sekar Kathiresan; Douglas P Kiel
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

9.  Serum osteoprotegerin levels are related to height loss: the Tromsø Study.

Authors:  Lone Jørgensen; John-Bjarne Hansen; Jan Brox; Ellisiv Mathiesen; Anders Vik; Bjarne K Jacobsen
Journal:  Eur J Epidemiol       Date:  2011-02-18       Impact factor: 8.082

10.  Clinical Data for Parametrization of In Silico Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature.

Authors:  Charles Ledoux; Daniele Boaretti; Akanksha Sachan; Ralph Müller; Caitlyn J Collins
Journal:  Front Bioeng Biotechnol       Date:  2022-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.